Treatment of metabolic disorders in canine animals
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.
1. A method of treatment of a metabolic disorder in a canine animal comprising administering to the canine animal a composition comprising one or more active agents, where the one or more active agents consist of one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof;
wherein:
the one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene or a pharmaceutically acceptable form thereof represented by the following formula:
the metabolic disorder is one or more selected from the group consisting of ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences comprising hypertension, renal dysfunction and/or musculoskeletal disorders, and Syndrome X (metabolic syndrome); and
the one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof is administered at a dose of no greater than 2.0 mg/kg bodyweight.
2. The method of claim 1 , wherein the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or the development of metabolic disorder consequences prevented or progression is slowed or remission is achieved.
3. The method of claim 1 , wherein the metabolic disorder is selected from the group consisting of clinical conditions associated with pre-diabetes, insulin dependent diabetes mellitus and insulin resistance.
4. The method of claim 3 , wherein the clinical conditions are one or more conditions selected from the group consisting of ketoacidosis, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences comprising hypertension, renal dysfunction and/or musculoskeletal disorders, and Syndrome X (metabolic syndrome).
5. The method of claim 1 , wherein the canine animal is suffering from diabetes.
6. The method of claim 1 , wherein the canine animal is suffering from pre-diabetes or insulin dependent diabetes.
7. The method of claim 1 , wherein the canine animal is a dog.
8. The method of claim 1 , wherein the pharmaceutically acceptable form thereof is a crystalline complex between the one or more SGLT-2 inhibitors and one or more amino acids.
9. The method of claim 8 , wherein the one or more amino acids comprise proline.
10. The method of claim 8 , wherein the one or more amino acids comprise L-proline.
11. The method of claim 1 , wherein the one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof is administered orally or parenterally.
12. The method of claim 1 , wherein the one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof is administered once per day.
13. The method of claim 1 , wherein the one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof is administered at a dose of 0.01 to 1.0 mg/kg bodyweight.